Market Overview on G-Protein Coupled Bile Acid Receptor 1G-TGR5 or GPR131-Pipeline Review, H1 2016

G-Protein Coupled Bile Acid Receptor 1G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1-Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit G-Protein Coupled Bile Acid Receptor 1G or GPBAR1-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1)
- The report reviews G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report reviews latest news and deals related to G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Ardelyx, Inc. Intercept Pharmaceuticals, Inc. Torrent Pharmaceuticals Limited Venenum Biodesign

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###